Progressive erythrocytosis under lenvatinib treatment in patients with advanced hepatocellular carcinoma

被引：0
作者：
Laurence Legros
Alina Pascale
Catherine Guettier
Pirayeh Eftekhari
Yasmina Ben Merabet
Maryse Stang
Rachel Bossevot
Emma Goldschmidt
Ayhan Ulusakarya
Stephane Morisset
Maïté Lewin
Didier Samuel
Olivier Rosmorduc
机构：
[1] Hôpital Bicêtre,Department of Clinical Hematology
[2] AP-HP,Hepato
[3] INSERM UMRS-MD-1197,Biliary Department
[4] Université Paris-Saclay,Anatomic Pathology Department
[5] France Intergroupe Syndromes Myéloprolifératifs (FIM),Medical Oncology Department
[6] Hôpital Paul Brousse,Radiology Department
[7] AP-HP,undefined
[8] Hôpital Bicêtre,undefined
[9] AP-HP,undefined
[10] Hôpital Paul Brousse,undefined
[11] AP-HP,undefined
[12] Independent Biostatistician,undefined
[13] Hôpital Paul Brousse,undefined
[14] AP-HP,undefined
[15] INSERM U1193,undefined
[16] Université Paris-Saclay,undefined
[17] Sorbonne Université,undefined
来源：
Cancer Chemotherapy and Pharmacology | 2023年 / 91卷
关键词：
Hepatocellular carcinoma; Lenvatinib; Antiangiogenic drugs; Erythrocytosis; Erythropoietin; Thromboprophylaxis;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：337 / 344
页数：7
相关论文
共 135 条
[1]  
Sung H(2021)Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries CA Cancer J Clin 71 209-249
[2]  
Ferlay J(2018)Hepatocellular carcinoma Lancet 391 1301-1314
[3]  
Siegel RL(2008)Sorafenib in advanced hepatocellular carcinoma N Engl J Med 359 378-390
[4]  
Forner A(2018)Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial Lancet 391 1163-1173
[5]  
Reig M(2020)Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma N Engl J Med 382 1894-1905
[6]  
Bruix J(2017)Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial Lancet 389 56-66
[7]  
Llovet JM(2018)Cabozantinib in patients with advanced and progressing hepatocellular carcinoma N Engl J Med 379 54-63
[8]  
Ricci S(2014)Antitumor activity of lenvatinib (e7080): an angiogenesis inhibitor that targets multiple receptor tyrosine kinases in preclinical human thyroid cancer models J Thyroid Res 2014 638747-60
[9]  
Mazzaferro V(2014)Lenvatinib, an angiogenesis inhibitor targeting VEGFR/FGFR, shows broad antitumor activity in human tumor xenograft models associated with microvessel density and pericyte coverage Vasc Cell 6 18-2405
[10]  
Kudo M(2010)Modified RECIST (mRECIST) assessment for hepatocellular carcinoma Semin Liver Dis 30 52-245
12345678910